ArticleJournal of thoracic disease2025
Risk factors of up-Stage and lymph node metastasis for clinical stage IA3 non-small cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although segmentectomy has tended to be the choice of treatment for clinical stage (cStage) IA non-small cell lung cancer (NSCLC) patients with tumor diameter ≤20 mm, the validity of sublobar resection for early-stage NSCLC patients with tumor diameters of 20-30 mm is uncertain. In this study, we retrospectively evaluated risk factors that might predict up-Stage and lymph node metastasis in NSCLC patients with tumor diameter 20-30 mm who underwent pulmonary resection. Methods: Overall, 410 patients with cStage IA disease, including 108 with cStage IA3, were enrolled in this retrospective study, and the risk factors of recurrence, up-Stage, and lymph node metastasis were analyzed. Results: The rates of patients with up-Stage (53.7% Conclusions: The cancer inflammation index and maximum standardized uptake value were significant risk factors for recurrence, CTR and Ly were revealed to be risk factors for up-Stage, and PNI and Ly were risk factors for lymph node metastasis in cStage IA3 NSCLC patients. At present, the indication for segmentectomy should be carefully considered for cStage IA3 NSCLC patients with these risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.